Isocyclophosphamide
Diffuse Large B-Cell Lymphoma
Explore 253 assets in Diffuse Large B-Cell Lymphoma →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07389356CT.gov Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06905509CT.gov Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05821088CT.gov Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | — | Suspended | — | — | — |
NCT05784987CT.gov R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT05364424CT.gov A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma | — | Completed | — | — | — |
NCT05221645CT.gov Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT05348213CT.gov Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT04665765CT.gov Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04663347CT.gov Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | — | Active Not Recruiting | — | — | — |
Show 26 more trialsShow fewer
NCT04189952CT.gov Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | — | Terminated | — | — | — |
NCT03736616CT.gov Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | — | Unknown | — | — | — |
NCT03349346CT.gov Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | — | Withdrawn | — | — | — |
NCT03450343CT.gov Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma | — | Completed | — | — | — |
NCT03440567CT.gov Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03064867CT.gov Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03383406CT.gov A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma | — | Unknown | — | — | — |
NCT02471911CT.gov KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | — | Completed | — | — | — |
NCT02592876CT.gov Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | — | Terminated | — | — | — |
NCT02393157CT.gov Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | — | Recruiting | — | — | — |
NCT02329080CT.gov New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | — | Completed | — | — | — |
NCT02531841CT.gov High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma | — | Unknown | — | — | — |
NCT01959698CT.gov Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01453205CT.gov A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT01481272CT.gov Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | — | Completed | — | — | — |
NCT02412267CT.gov Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT01226849CT.gov Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT00823719CT.gov Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT00836173CT.gov Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT00601718CT.gov Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00529503CT.gov A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | — | Terminated | — | — | — |
NCT00324467CT.gov Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | — | Unknown | — | — | — |
NCT00086944CT.gov Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00842595CT.gov Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | — | Completed | — | — | — |
NCT00137995CT.gov R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | — | Completed | — | — | — |
NCT00187070CT.gov Large Cell Lymphoma Pilot Study III | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isocyclophosphamide (this asset) | The First Affiliated Hospital with Nanjing Medical University | Approved | BB · 68 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| (+)-Vincristine | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Isocyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Angioimmunoblastic T-Cell Lymphoma | — | P4 | BBB · 76 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isocyclophosphamide in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isocyclophosphamide-diffuse-large-b-cell-lymphoma-123209
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →